VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Phase 1/2 Clinical Study in Patients
Creator
Raymond Douglas; Kimberley Cockerham; Roger Turbin; Rosa Tang; Navdeep Nijhawan Shoaib Ugradar; Denis O'Shaughnessy; Rochelle Summerfelt; Angela She; Barrett Katz
Affiliation
(RD) (SU) Cedars Sinai Medical Center; (KC) Senta Clinic; (RT) Rutgers New Jersey Medical School - Department of Ophthalmology & Visual Science; (RT) Eye Wellness Center- Neuro-Eye Clinical Trials, Inc.; (NN) Oshawa Clinic; (DO) (RS) (AS) (BK) Viridian Therapeutics Inc.
Clinical and preclinical evidence confirms IGF-1R antagonism reduces TED-related inflammation and proptosis. VRDN-001, a full antagonist antibody to IGF-1R, is being evaluated in a phase 1/2 double-masked, randomized clinical trial (NCT05176639) at 3, 10, or 20 mg/kg administered intravenously. Results from the first cohort of TED patients are presented here.
Date
2023-03
References
None provided.
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
49th Annual North American Neuro-Ophthalmology Society Annual Meeting
